Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer Patients

ZHAO Ruihua; LI Xiangke; ZHANG Weijie

doi:10.3971/j.issn.1000-8578.2014.10.007

Cancer Research on Prevention and Treatment > 2014 > 41(10): 1087-1092. > DOI: 10.3971/j.issn.1000-8578.2014.10.007

ZHAO Ruihua, LI Xiangke, ZHANG Weijie. Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2014, 41(10): 1087-1092. DOI: 10.3971/j.issn.1000-8578.2014.10.007

Citation:

PDF (600 KB)

Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer Patients

Department of Oncology, The First Affiliated Hospital of Zhengzhou University Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

More Information

Received Date: August 22, 2013
Revised Date: January 09, 2014

Graphical Abstract

Abstract

Abstract

Objective To explore the possibility of plasma miR-221 as a biomarker for chemosensitivity to neoadjuvant chemotherapy(NAC) in breast cancer patients. Methods The expression levels of circulating plasma miR-221 in 32 healthy individuals and 93 breast cancer patients who received NAC were assessed by QRT-PCR method. The correlation between miR-221 expression levels and clinicalpathological features and chemosensitivity were also analysed. Results miR-221 expression levels in the plasma of breast cancer patients(1.453±0.065) were significantly higher than those in healthy individuals (1.114±0.093)(P=0.007). miR-221 expression level was significantly associated with hormone receptor(HR) status (P=0.008). Patients with higher plasma miR-221 levels tended to be with HR-negative. Patients with different miR-221 levels had significant differences in overall response rate (ORR), not complete response (pCR) rate (ORR:P=0.044; pCR: P=0.477). Conclusion Plasma miR-221 expression may be a predictive biomarker for chemosensitivity to NAC in breast cancer patients.
- miR-221,
- Breast cancer,
- Neoadjuvant chemotherapy

FullText(HTML)

References (30)

References

[1]	Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol, 1997,15(7):2483-93.
[2]	Wolmark N, Wang J, Mamounas E,et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr, 2001,(30):96-102.
[3]	Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy[J]. J Clin Oncol, 1999,17(2):460-9.
[4]	Pierga JY, Mouret E, Diéras V, et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer[J]. Br J Cancer, 2000,83(11):1480-7.
[5]	Colleoni M, Bagnardi V, Rotmensz N, et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy[J]. Breast Cancer Res Treat, 2009,116(2):359-69.
[6]	Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005,11(16):5678-85.
[7]	Precht LM, Lowe KA, Atwood M, et al. Neoadjuvant chemotherapy of breast cancer: tumor markers as predictors of pathologic response, recurrence, and survival[J]. Breast J, 20 10,16(4):362-8.
[8]	Katz A, Saad ED, Porter P, et al. Primary systemic chemotherapy of invasive lobular carcinoma of the breast[J]. Lancet Oncol, 20 07,8(1):55-62.
[9]	Bonnefoi H, Potti A, Delorenzi M, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00 -01 clinical trial[J]. Lancet Oncol, 2007,8(12):1071-8.
[10]	Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18[J]. Cancer, 20 02,95(4):681-95.
[11]	Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004,116(2):281-97.
[12]	Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res, 2008,18(10):997-1006.
[13]	Mouillet JF, Chu T, Hubel CA, et al. The levels of hypoxiaregulated microRNAs in plasma of pregnant women with fetal growth restriction[J]. Placenta,2010,31(9):781-4.
[14]	Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases[J]. Expert Opin Biol Ther, 2009,9(6):703-11.
[15]	Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27kip1[J]. J Biol Chem, 20 07,282(32):23716-24.
[16]	Zhao JJ, Lin J, Yang H, et al. microRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer[J]. J Biol Chem, 20 08,283(45):31079-86.
[17]	Cui XY, Guo YJ, Yao HR. Analysis of microRNA in drug-resistant breast cancer cell line MCF-7/ADR[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2008,28(10):1813-5.[崔秀英，郭运杰，姚和瑞. 耐药乳腺癌细胞株MCF-7/ADR中microRNA的分析[J]. 南方医科大学学报, 2008,28(10):1813-5]
[18]	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada[J]. J Natl Cancer Inst, 2000,92(3):205-16.
[19]	Elston CW, Ellis IO. Pathological prognostic factors in breast cancer.Ⅰ. The value of histological grade in breast cancer: experience from a large study with long-term follow-up[J]. Histop athology,1991,19(5):403-10.
[20]	Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression[J]. J Gastroenterol Hepatol,2010,25(10):1674-80.
[21]	He H, Jazdzewski K, Li W,et al. The role of microRNA genes in papillary thyroid carcinoma[J]. Proc Natl Acad Sci U S A, 20 05,102(52):19075-80.
[22]	Zhao JJ, Lin J, Yang H, et al. microRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer[J]. J Biol Chem, 20 08,283(45):31079-86.
[23]	Di Leva G, Gasparini P, Piovan C, et al. microRNA cluster 22 1-222 and estrogen receptor alpha interactions in breast cancer[J]. J Natl Cancer Inst,2010,102(10):706-21.
[24]	Rao X, Di Leva G, Li M,et al. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways[J]. Oncogene, 2011,30(9):1082-97.
[25]	Ach RA, Wang H, Curry B. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods[J]. BMC Biotechnol,2008,8:69.
[26]	Bhargava R, Beriwal S, Dabbs DJ,et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases[J]. Cancer,2010,116(6):1431-9.
[27]	Zhu L, Li YF, Chen WG,et al. HER2 and topoisomerase Ⅱalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients[J]. Chin Med J (Engl), 20 08,121(20):1965-8.
[28]	Konecny GE, Pauletti G, Untch M,et al. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer[J]. Breast Cancer Res Treat,2010,120(2):481-9.
[29]	Nishimura R, Osako T, Okumura Y,et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis[J]. Breast Cancer, 2010,17(4):269-75.
[30]	von Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast[J]. Breast Cancer Res,2008,10(2):R30.

[1]	LU Mei, YANG Xiaojuan, ZOU Jieya, GUO Rong, WANG Xin, ZHANG Qian, DENG Xuepeng, TAO Jianfen, NIE Jianyun, YANG Zhuangqing. Efficacy Prediction Model for Neoadjuvant Chemotherapy on Breast Cancer Based on Differential Genes Expression[J]. Cancer Research on Prevention and Treatment, 2021, 48(12): 1071-1077. DOI: 10.3971/j.issn.1000-8578.2021.21.0414
[2]	WU Jianzhong, CHEN Lin, LIU Xiaoan, GAO Quangen, HUANG Weixian. Tumor-infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma[J]. Cancer Research on Prevention and Treatment, 2015, 42(11): 1114-1118. DOI: 10.3971/j.issn.1000-8578.2015.11.012
[3]	LV Minhao, QIN Li, LI Juntao, GUO Xuhui, LIU Fawen, CUI Shude, ZHANG Hengwei. 原发性乳腺癌分子分型与新辅助化疗疗效及预后的相关性[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 782-788. DOI: 10.3971/j.issn.1000-8578.2015.08.007
[4]	ZHANG Yanshou, LIU Yunjiang. Correlation between BCRP Expression and Efficacy of Neoadjuvant Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2014, 41(05): 434-438. DOI: 10.3971/j.issn.1000-8578.2014.05.020
[5]	FengYanlin, Lu Shengnan, Yang Jie, Xian Weijun. Valuation of 18F-FDG PET/CT in Predicting Pathological Reaction of Neoadjuvant Chemotherapy with Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(10): 1224-1227. DOI: 10.3971/j.issn.1000-8578.2012.10.015
[6]	Zhou Xin, Wu Chengyi. Relationship of CD44^＋/CD24^－/low with Responsiveness of Breast Cancer to Anthracycline-based Chemotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 966-969. DOI: 10.3971/j.issn.1000-8578.2012.08.021
[7]	WU Xin-hong, FENG Yao-jun, PAN Cui-ping, XU Juan, ZHONG Wei, SHAO Jun, MA Biao. Alteration of Biomarker HER-2 between Pre-and Post-neoadjuvant Chemotherapy in Breast Cancer Patients[J]. Cancer Research on Prevention and Treatment, 2011, 38(08): 930-932. DOI: 10.3971/j.issn.1000-8578.2011.08.019
[8]	ZHAO Yu-bin, ZHANG Shao-hua, ZHANG Ji-ren, WANG Jin-qing. Effect and Clinical Significance of Neoadjuvant Chemotherapy on Expression of ER,PR and EphA2 in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2010, 37(04): 457-460. DOI: 10.3971/j.issn.1000-8578.2010.04.024
[9]	YANG Hai-song, HUANG Jian-jun. Effects of Neoadjuvant Chemotherapy on P-gp,GST-π Expression in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2009, 36(02): 147-149. DOI: 10.3971/j.issn.1000-8578.2009.02.018
[10]	WANG Kun, WU Yi-long, ZHENG Deng-yun, LIAO Ning, ZU Jian, LI Xue-rui, LIN Xue-ting. Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients by Using Molecular Markers[J]. Cancer Research on Prevention and Treatment, 2008, 35(02): 118-120. DOI: 10.3971/j.issn.1000-8578.2039

Cited By

Get Citation

PDF

XML

Article views (1056) PDF downloads (431)

Turn off MathJax

Article Contents

Abstract

References

Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer Patients

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Plasma miR-221 Expression could Predict Chemosensitivity to Neoadjuvant Chemotherapy in Breast Cancer Patients

Abstract

References

Related Articles

Catalog

Download Center

Links

Contact Us

Export File

Citation

Format

Content